The Management of Metastatic Differentiated Thyroid Carcinoma

Reviews in Endocrine and Metabolic Disorders

Volumn 1, Issue 3, 2000, Pages 165-171

  Sherman, Steven I ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Differentiated thyroid carcinoma; Metastases; Radiation therapy; Surgery; Systemic therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL RESPONSE MODIFIER; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; THYROGLOBULIN;

ADENOCARCINOMA; BLOOD; HUMAN; METASTASIS; PAPILLARY CARCINOMA; PATHOLOGY; RADIOTHERAPY; REVIEW; SURGERY; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; ANTINEOPLASTIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; CARCINOMA, PAPILLARY; HUMANS; IODINE RADIOISOTOPES; NEOPLASM METASTASIS; RADIOTHERAPY; SURGICAL PROCEDURES, OPERATIVE; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 0034173352     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010074930254     Document Type: Article

References (50)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999 CA Cancer. J Clin 1999;49:8-31.
2. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of treatment of thyroid carcinoma initial analysis of staging and outcome. Cancer 1998;83:1012-1021.
3. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306.
4. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999;9:421-427.
5. Hay ID, Klee GG. Thyroid cancer diagnosis and management. Clin Lab Med 1993;13:725-734.
6. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID. Distant metastases in papillary thyroid carcinoma 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 1995;80:2041-2045.
7. Vassilopoulou-Sellin R, Schultz PN, Haynie TP. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 1996;78:493-501.
8. Grebe SK, Hay ID. Thyroid cancer nodal metastases biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996;5:43-63.
9. Simon D, Goretzki PE, Witte J, Roher HD. Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma. World J Surg 1996;20:860-866.
10. McCaffrey TV, Bergstralh EJ, Hay ID. Locally invasive papillary thyroid carcinoma 1940-1990. Head Neck 1994;16:165-172.
11. Park CS, Suh KW, Min JS. Cartilage-shaving procedure for the control of tracheal cartilage invasion by thyroid carcinoma. Head Neck 1993;15:289-291.
12. Gillenwater AM, Goepfert H. Surgical management of laryngotracheal and esophageal involvement by locally advanced thyroid cancer. Semin Surg Oncol 1999;16:19-29.
13. Niederle B, Roka R, Schemper M, Fritsch A, Weissel M, Ramach W. Surgical treatment of distant metastases in differentiated thyroid cancer indication and results. Surgery 1986;100:1088-1097.
14. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Chin Endocrinol Metal 1997;82:3637-3642.
15. Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer - A quantitative radiation dosimetric approach: Outcome and validation in 85 patients. J Nucl Med 1992;33:1132-1136.
16. Maxon HR, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastic well differentiated thyroid cancer. Endocrinol Metal Clin North Am 1990;19:685-718.
17. Sisson JC, Giordano TJ, Jamadar DA, et al. 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer 1996;78:2184-2192.
18. Sisson JC, Jamadar DA, Kazerooni EA, Giordano TJ, Carey JE, Spaulding SA. Treatment of micronodular lung metastases of papillary thyroid cancer: are the tumors too small for effective irradiation from radioiodine? Thyroid 1998;8:215-221.
19. Furhang EE, Larson SM, Buranapong P, Humm JL. Thyroid cancer dosimetry using clearance fitting. J Nucl Med 1999;40:131-136.
20. Bohuslavizki KH, Klutmann S, Brenner W, Mester J, Henze E, Clausen M. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-bind placebo-controlled study. J Clin Oncol 1998;16:3542-3549.
21. Vassilopoulou-Sellin R, Palmer L, Taylor S, Cooksley CS. Incidence of breast carcinoma in women with thyroid carcinoma. Cancer 1999;85:696-705.
22. de Vathaire F, Schlumberger M, Delisle MJ, et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 1997;75:734-739.
23. Koong SS, Reynolds JC, Movius EG, et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999;84:912-916.
24. Schmutzler C, Brtko J, Bienert K, Kohrle J. Effects of retinoids and role of retinoic acid receptors in human thyroid carcinomas and cell lines derived therefrom. Exp Clin Endocrinol Diabet 1996;104:16-19.
25. Van Herle AJ, Agatep ML, Padua DNd, et al. Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82 W-1) in vitro. J Clin Endocrinol Metab 1990;71:755-763.
26. Ledger G, Mullan BP, O'Connor MK, et al. Pilot study on the use of 13-cis-retinoic acid (isotretinoin) as an adjunct to radioiodine therapy of metastatic thyroid cancer. (Abstract #867) 76th Annual Meeting of The Endocrine Society Anaheim, CA, 1994, 417.
27. Simon D, Kohrle J, Schmutzler C, Mainz K, Reiners C, Roher H-D. Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid basics and first clinical results. Exp Clin Endocrinol Diabet 1996;104:13-15.
28. Simon D, Koehrle J, Reiners C, et al. Redifferentiation therapy with retinoids therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998;22:569-574.
29. Venkataraman GM, Yatin M, Marcinek R, Ain KB. Restoration of iodide uptake in dedifferentiated thyroid carcinoma relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 1999;84:2449-2457.
30. Morris JC, Kim CK, Padilla ML, Mechanick JI. Conversion of non-iodine-concentrating differentiated thyroid carcinoma metastases into iodine-concentrating foci after anticancer chemotherapy. Thyroid 1997;7:63-66.
31. Misaki T, et al. Tumoricidal cytokines enhance radioiodine uptake in cultured thyroid. J Nucl Med 1996;37:646-648.
32. Pujol P, Daures J-P, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996;81:4318-4323.
33. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998;8:737-744.
34. Biondi B, Fazio S, Cuocolo A, et al. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1996;81:4224-4228.
35. Shapiro LE, Sievert R, Ong L, et al. Minimal cardiac effects in asymptomatic athreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab 1997;82:2592-2595.
36. Sherman SI, Chiu AC, Kopelen H, Zoghbi W. Minimal resting cardiac effects of TSH-suppressive doses of L-thyroxine. Thyroid 1997;7:S58.
37. Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998;82:375-388.
38. Farahati J, Reiners C, Stuschke M, et al. Differentiated thyroid cancer Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 1996;77:172-180.
39. Brierley JD, Tsang RW. External-beam radiation therapy in the treatment of differentiated thyroid cancer. Semin Surg Oncol 1999;16:42-49.
40. Wartofsky L, ed. Thyroid Cancer: A Comprehensive Guide to Clinical Management Totowa. NJ: Humana Press, 1999.
41. Schlumberger M, Pacini F. Thyroid Tumors. Gif-sur-Yvette Cedex. France: Nucleon, 1999.
42. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999;16:34-41.
43. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155-2160.
44. Bukowski RM, Brown L, Weick JK, Groppe CW, Purvis J. Combination chemotherapy of metastatic thyroid cancer. Phase II study. Am J Clin Oncol 1983;6:579-581.
45. Schlumberger M, Mancusi F, Baudin E, Pacini F. 131I therapy for elevated thyroglobulin levels. Thyroid 1997;7:273-276.
46. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:1488-1492.
47. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ. Serum thyroglobulin in the follow-up of patients treated with differentiated thyroid cancer. J Clin Endocrinol Metab 1994;79:98-105.
48. Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid 1997;7:183-188.
49. Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 1998;83:4195-4203.
50. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84:2291-2302.